mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 1, 2011, Pages

  Belibi, Franck ^a   Ravichandran, Kameswaran ^a   Zafar, Iram ^a   He, Zhibin ^a   Edelstein, Charles L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Autosomal dominant polycystic kidney disease; Cyst volume; Kidney size

Indexed keywords

CASPASE 3; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN KINASE D; PROTEIN S6; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GENE ACTIVATION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 78651303135     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00129.2010     Document Type: Article

References (40)

1. Alessi DR, Pearce LR, Garcia-Martinez JM. New insights into mTOR signaling: mTORC2 and beyond. Sci Signal 2: pe27, 2009.
2. Boletta A. Emerging evidence of a link between the polycystins and the mTOR pathways. Pathogenetics 2: 6, 2009.
3. Calvet JP. Strategies to inhibit cyst formation in ADPKD. Clin J Am Soc Nephrol 3: 1205-1211, 2008.
4. Cowley BD Jr, Chadwick LJ, Grantham JJ, Calvet JP. Elevated proto-oncogene expression in polycystic kidneys of the C57BL/6J (cpk) mouse. J Am Soc Nephrol 1: 1048-1053, 1991.
5. Cowley BD Jr, Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, Gattone VH 2nd. Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 43: 522-534, 1993. (Pubitemid 23071934)
6. Cowley BD Jr, Rupp JC, Muessel MJ, Gattone VH 2nd. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. Am J Kidney Dis 29: 265-272, 1997.
7. Cowley BD Jr, Smardo FL Jr, Grantham JJ, Calvet JP. Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease. Proc Natl Acad Sci USA 84: 8394-8398, 1987. [Erratum. Proc Natl Acad Sci USA 85 (Apr): 2578, 1988.]
8. Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 29: 5657-5670, 2009.
9. Ecder T, Fick-Brosnahan G, Schrier RW. Polycystic kidney disease. In: Diseases of the Kidney and Urinary Tract, edited by Schrier RW. Philadelphia: Lippincott, Williams & Wilkins, 2007, p. 502-539.
10. Edelstein CL. What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)? Cell Cycle 4: e141-e145, 2005.
11. Faubel SG, Ljubanovic D, Reznikov LL, Somerset H, Dinarello CA, Edelstein CL. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 66: 2202-2213, 2004.
12. Ferrari S, Bandi HR, Hofsteenge J, Bussian BM, Thomas G. Mitogen-activated 70K S6 kinase. Identification of in vitro 40S ribosomal S6 phosphorylation sites. J Biol Chem 266: 22770-22775, 1991.
13. Fischer DC, Jacoby U, Pape L, Ward CJ, Kuwertz-Broeking E, Renken C, Nizze H, Querfeld U, Rudolph B, Mueller-Wiefel DE, Bergmann C, Haffner D. Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). Nephrol Dialysis Transplant 24: 1819-1827, 2009.
14. Flotow H, Thomas G. Substrate recognition determinants of the mitogen-activated 70K S6 kinase from rat liver. J Biol Chem 267: 3074-3078, 1992.
15. Gangoiti P, Granado MH, Arana L, Ouro A, Gomez-Munoz A. Activation of protein kinase C-α is essential for stimulation of cell proliferation by ceramide 1-phosphate. FEBS Lett 584: 517-524, 2010.
16. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev Cell 11: 859-871, 2006.
17. Ibrahim S. Increased apoptosis and proliferative capacity are early events in cyst formation in autosomal-dominant, polycystic kidney disease. Sci World J 7: 1757-1767, 2007.
18. Kawakami Y, Kitaura J, Yao L, McHenry RW, Kawakami Y, Newton AC, Kang S, Kato RM, Leitges M, Rawlings DJ, Kawakami T. A Ras activation pathway dependent on Syk phosphorylation of protein kinase C. Proc Natl Acad Sci USA 100: 9470-9475, 2003.
19. Kovacs J, Gomba S. Analysis of the role of apoptosis and cell proliferation in renal cystic disorders. Kidney Blood Press Res 21: 325-328, 1998. (Pubitemid 28517822)
20. Kranzlin B, Schieren G, Gretz N. Azotemia and extrarenal manifestations in old female Han:SPRD (cy/+) rats. Kidney Int 51: 1160-1169, 1997.
21. Murcia NS, Sweeney WE Jr, Avner ED. New insights into the molecular pathophysiology of polycystic kidney disease. Kidney Int 55: 1187-1197, 1999.
22. Nagao S, Kusaka M, Marunouchi T, Kurahashi H, Takahashi H, Grantham J. Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease. Kidney Int 16: 2052-2062, 2005.
23. Ramasubbu K, Gretz N, Bachmann S. Increased epithelial cell proliferation and abnormal extracellular matrix in rat polycystic kidney disease. J Am Soc Nephrol 9: 937-945, 1998. (Pubitemid 28264720)
24. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168, 2006.
25. Schafer K, Gretz N, Bader M, Oberbaumer I, Eckardt KU, Kriz W, Bachmann S. Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease. Kidney Int 46: 134-152, 1994. (Pubitemid 24210445)
26. Schaffner DL, Barrios R, Massey C, Banez EI, Ou CN, Rajagopalan S, Aguilar-Cordova E, Lebovitz RM, Overbeek PA, Lieberman MW. Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. Am J Pathol 142: 1051-1060, 1993.
27. Shi Y, Melnikov VY, Schrier RW, Edelstein CL. Downregulation of the calpain inhibitor protein calpastatin by caspases during renal ischemia-reperfusion. Am J Physiol Renal Physiol 279: F509-F517, 2000.
28. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 103: 5466-5471, 2006.
29. Stringer K, Komers R, Osman SA, Oyama TT, Lindsley JN, Anderson S. Gender hormones and the progression of experimental polycystic kidney disease. Kidney Int 68: 1729-1739, 2005.
30. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease (PKD). J Am Soc Nephrol 16: 46-51, 2005.
31. Tao Y, Kim J, Faubel S, Wu JC, Falk SA, Schrier RW, Edelstein CL. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease (PKD). Proc Natl Acad Sci USA 102: 6954-6959, 2005.
32. Torres VE, Harris PC. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2: 40-55, 2006.
33. Trudel M, Barisoni L, Lanoix J, D'Agati V. Polycystic kidney disease in SBM transgenic mice: role of c-myc in disease induction and progression. Am J Pathol 152: 219-229, 1998.
34. Trudel M, D'Agati V, Costantini F. c-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int 39: 665-671, 1991.
35. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21: 598-604, 2006.
36. Wilson PD. Polycystic kidney disease. N Engl J Med 350: 151-164, 2004.
37. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 30: 253-259, 2007.
38. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.
39. Zafar I, Belibi FA, He Z, Edelstein CL. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 24: 2349-2353, 2009.
40. Zeng Z, Sarbassov D, Samudio IJ, Yee KW, Munsell MF, Ellen JC, Giles FJ, Sabatini DM, Andreeff M, Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109: 3509-3512, 2007.